P53 activation mediates polyglutamine-expanded ataxin-3 upregulation of Bax expression in cerebellar and pontine nuclei neurons

Neurochemistry International

Volumn 58, Issue 2, 2011, Pages 145-152

  Chou, An Hsun ^a   Lin, An Chi ^b   Hong, Kue Yi ^b   Hu, Su Huei ^b   Chen, Ying Ling ^b,c   Chen, Ju Yu ^b   Wang, Hung Li ^b  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b CHANG GUNG UNIVERSITY   (Taiwan)

^c CHANG GUNG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Taiwan)

Author keywords

Bax; Cerebellum; p53; Polyglutamine expanded ataxin 3; Pontine nuclei; Spinocerebellar ataxia type 3

Indexed keywords

ATAXIN 3; MESSENGER RNA; MUTANT PROTEIN; PIFITHRIN ALPHA; POLYGLUTAMINE; PROTEIN BAX; PROTEIN P53; PUMA PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; ELECTROPHORETIC MOBILITY; GEL MOBILITY SHIFT ASSAY; GENE MUTATION; GENETIC TRANSCRIPTION; MALE; MOUSE; NERVE CELL; NERVE CELL NECROSIS; NERVE DEGENERATION; NEWBORN; NONHUMAN; PONTINE NUCLEUS; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN PHOSPHORYLATION; RAT; SPINOCEREBELLAR DEGENERATION; TRANSCRIPTION REGULATION; TRANSGENIC MOUSE; UPREGULATION;

ANIMALS; ANIMALS, NEWBORN; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CEREBELLUM; DISEASE MODELS, ANIMAL; HUMANS; MICE; MICE, TRANSGENIC; NERVE TISSUE PROTEINS; NEURONS; NUCLEAR PROTEINS; PHOSPHORYLATION; PONS; RATS; REPRESSOR PROTEINS; RNA, MESSENGER; TRANSCRIPTIONAL ACTIVATION; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION;

ANIMALIA; MUS MUSCULUS;

EID: 78651254160     PISSN: 01970186     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuint.2010.11.005     Document Type: Article

References (28)

1. C. Alves da Costa, C. Sunyach, R. Pardossi-Piquard, J. Sevalle, B. Vincent, N. Boyer, T. Kawarai, N. Girardot, P. George-Hyslop, and F. Checler Presenilin-dependent γ-secretase-mediated control of p53-associated cell death in Alzheimer's disease J. Neurosci. 26 2006 6377 6385
2. B.I. Bae, H. Xu, S. Igarashi, M. Fujimoto, N. Agrawai, Y. Taya, S.D. Hayward, T.H. Moran, C. Montell, C.A. Ross, S.H. Snyder, and A. Sawa p53 mediates cellular dysfunction and behavioral abnormalities in Huntington's disease Neuron 47 2005 29 41
3. J.E. Chipuk, and D.R. Green Dissecting p53-dependent apoptosis Cell Death Differ. 13 2006 94 1002
4. A.H. Chou, T.H. Yeh, Y.L. Kuo, Y.C. Kao, M.J. Jou, C.Y. Hsu, S.R. Tsai, A. Kakizuka, and H.L. Wang Polyglutamine-expanded ataxin-3 activates mitochondrial apoptotic pathway by upregulating Bax and downregulating Bcl-xL Neurobiol. Dis. 21 2006 335 345
5. A.H. Chou, T.H. Yeh, P. Ouyang, Y.L. Chen, S.Y. Chen, and H.L. Wang Polyglutamine-expanded ataxin-3 causes cerebellar dysfunction of SCA3 transgenic mice by inducing transcriptional dysregulation Neurobiol. Dis. 31 2008 89 101
6. S.P. Cregan, N.A. Arbour, J.G. Maclaurin, S.M. Callaghan, A. Fortin, E.C. Cheung, D.S. Guberman, D.S. Park, and R.S. Slack p53 activation domain 1 is essential for PUMA upregulation and p53-mediated neuronal cell death J. Neurosci. 24 2004 10003 10012
7. C. Culmsee, X. Zhu, Q.S. Yu, S.L. Chan, S. Camandola, Z. Guo, N.H. Greig, and M.P. Mattson A synthetic inhibitor of p53 protects neurons against death induced by ischemic and excitotoxic insults, and amyloid β-peptide J. Neurochem. 77 2001 220 228
8. C. Culmsee, and M.P. Mattson p53 in neuronal apoptosis Biochem. Biophys. Res. Commun. 331 2005 761 777
9. A. Durr, G. Stevanin, G. Cancel, C. Duyckaerts, N. Abbas, O. Didierjean, H. Chneiweiss, A. Benomar, O. Lyon-Caen, J. Julien, M. Serdaru, C. Penet, Y. Agid, and A. Brice Spinocerebellar ataxia 3 and Machado-Joseph disease: clinical, molecular, and neuropathological features Ann. Neurol. 39 1996 490 499
10. C.M. Everett, and N.W. Wood Trinucleotide repeats and neurodegenerative disease Brain 127 2004 2385 2405
11. J.S. Fridman, and S.W. Lowe Control of apoptosis by p53 Oncogene 22 2003 9030 9040
12. J.L. Gonzalez de Aguilar, J.W. Gordon, F. Rene, M. de Tapia, B. Lutz-Bucher, C. Gaiddon, and J.P. Loeffler Alteration of the Bcl-x/Bax ratio in a transgenic mouse model of amyotrophic lateral sclerosis: evidence for the implication of the p53 signaling pathway Neurobiol. Dis. 7 2000 406 415
13. L.J. Hofseth, S.P. Hussain, and C.C. Harris p53: 25 years after its discovery Trends Pharmacol. Sci. 25 2004 177 181
14. Y. Kawaguchi, T. Okamoto, M. Taniwaki, M. Aizawa, M. Inoue, S. Katayama, H. Kawakami, S. Nakamura, M. Nishimura, I. Akiguchi, J. Kimura, S. Narumiya, and A. Kakizuka CAG expansions in a novel gene for Machado-Joseph disease at chromosome 14q32.1 Nat. Genet. 8 1994 221 228
15. T. Kobayashi, and A. Kakizuka Molecular analysis of Machado-Joseph disease Cytogenet. Genome Res. 100 2003 261 275
16. M.F. Lavin, and N. Gueven The complexity of p53 stabilization and activation Cell Death Differ. 13 2006 941 950
17. R.S. Morrison, Y. Konoshita, M.D. Johnson, W. Guo, and G.A. Garden p53-dependent cell death signaling in neurons Neurochem. Res. 28 2003 15 27
18. E. Munoz, M.J. Rey, M. Mila, A. Cardozo, T. Ribalta, E. Tolosa, and I. Ferrer Intranuclear inclusions, neuronal loss and CAG mosaicism in two patients with Machado-Joseph disease J. Neurol. Sci. 200 2002 19 25
19. H.T. Orr, and H.Y. Zoghbi Trinucleotide repeat disorders Annu. Rev. Neurosci. 30 2007 576 621
20. K.S. Panickar, A.R. Jayakumar, K.V. Rao, and M.D. Norenberg Ammonia-induced activation of p53 in cultured astrocytes: role in cell swelling and glutamate uptake Neurochem. Int. 55 2009 98 105
21. C. Perier, J. Bove, D.C. Wu, B. Dehay, D.K. Choi, V. Jackson-Lewis, S. Rathke-Hartlie, P. Bouillet, A. Strasser, J.B. Schulz, S. Przedborski, and M. Vila Two molecular pathways initiate mitochondria dependent dopaminergic neurodegeneration in experimental Parkinson's disease Proc. Natl. Acad. Sci. U.S.A. 104 2007 8161 8166
22. N. Plesnila, L. von Baumgarten, M. Retiounskaia, D. Engel, A. Ardeshiri, R. Zimmermann, F. Hoffmann, S. Landshamer, E. Wagner, and C. Culmsee Delayed neuronal death after brain trauma involves p53-dependent inhibition of NF-κB transcriptional activity Cell Death Differ. 14 2007 1529 1541
23. R.M. Ramalho, P.S. Ribeiro, S. Sola, R.E. Castro, C.J. Steer, and C.M.P. Rodrigues Inhibition of the E2F-1/p53/Bax pathway by tauroursodeoxycholic acid in amyloid β-peptide-induced apoptosis in PC12 cells J. Neurochem. 90 2004 567 575
24. O. Riess, U. Rüb, A. Pastore, P. Bauer, and L. Schöls SCA3: neurological features, pathogenesis and animal models Cerebellum 7 2008 125 137
25. T. Uo, Y. Kinoshita, and R.S. Morrison Apoptotic actions of p53 require transcriptional activation of PUMA and do not involve a direct mitochondrial/cytoplasmic site of action in postnatal cortical neurons J. Neurosci. 27 2007 12198 12210
26. H.L. Wang, T.H. Yeh, A.H. Chou, Y.L. Kuo, L.J. Luo, C.Y. He, P.C. Huang, and A.H. Li Polyglutamine-expanded ataxin-7 activates mitochondrial apoptotic pathway of cerebellar neurons by upregulating Bax and downregulating Bcl-xL Cell. Signal. 18 2006 541 552
27. H.L. Wang, A.H. Chou, A.C. Lin, S.Y. Chen, Y.H. Weng, and T.H. Yeh Polyglutamine-expanded ataxin-7 upregulates Bax expression by activating p53 in cerebellar and inferior olivary neurons Exp. Neurol. 224 2010 486 494
28. J. Yu, and L. Zhang PUMA, a potent killer with or without p53 Oncogene 27 2009 S71 S83